I

Ionis Pharmaceuticals
D

IONS

42.240
USD
0.10
(0.24%)
مغلق
حجم التداول
33,497
الربح لكل سهم
-3
العائد الربحي
-
P/E
-14
حجم السوق
6,722,880,342
أصول ذات صلة
ALNY
ALNY
1.29
(0.39%)
329.01 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
GILD
GILD
3.000
(2.65%)
116.210 USD
MRNA
MRNA
0.125
(0.37%)
34.145 USD
REGN
REGN
-1.20
(-0.21%)
563.22 USD
S
SGMO
-0.01190
(-1.99%)
0.58600 USD
S
SRPT
-0.970
(-7.53%)
11.910 USD
VRTX
VRTX
-2.89
(-0.61%)
469.58 USD
المزيد
الأخبار المقالات

العنوان: Ionis Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.